Top 17 respiratory device investors across Europe
Top 17 respiratory device investors across Europe
The respiratory device industry in Europe is focused on creating technologies that help patients breathe better. Companies range from startups to established firms, producing equipment like inhalers, nebulizers, and ventilators. With an aging population and rising respiratory illnesses, the demand for innovative solutions is increasing. Growth is fueled by advancements in smart technology and data connectivity, enhancing treatment precision. Moreover, environmental considerations are driving efforts towards sustainable manufacturing practices. The future holds promise as the industry aims to improve quality of life while addressing health care efficiencies amidst growing competition.
In 2024, a variety of investors shaped the respiratory device sector in Europe, with venture capital firms, corporate entities, and public organizations contributing significantly. Headquartered across Belgium, France, Denmark, and the UK, these investors range from small teams to large institutions, focusing on companies that innovate in respiratory care. Together, the 17 featured investors executed over 450 deals, showcasing a robust interest in advancing medical technologies that improve patient outcomes. Founded from 1953 to 2015, they cover a wide spectrum of investment types, emphasizing the dynamism within this vital healthcare segment.
Top 17 Respiratory Device Investors in Europe
1. European Innovation Council (EIC)
- Website: eic.ec.europa.eu
- Type: Corporate
- Headquarters: Brussels, Brussels, Belgium
- Founded year: 1958
- Headcount: 201-500
- Number of deals in 2024: 57
- LinkedIn: european-innovation-council-eic
The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, founded in 1958, that supports innovation and entrepreneurship across Europe. It offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, the EIC has made significant investments in the respiratory device industry, including a 5 million euro investment in the Israeli medical startup NanoVation, which focuses on developing a respiratory monitor. This investment is part of the EIC's strategy to support high-impact startups and small companies in the healthcare sector. Additionally, the EIC has provided grants to Respinova, further emphasizing its commitment to advancing respiratory health technologies.
2. Bpifrance French Tech Accélération
- Website: bpifrance.com
- Type: Venture Capital
- Headquarters: Paris, Île-De-France, France
- Founded year: 2015
- Headcount: 1-10
- Number of deals in 2024: 198
- LinkedIn: bpifrance-french-tech-acc%c3%a9l%c3%a9ration
Bpifrance French Tech Accélération is a venture capital firm based in Paris, Île-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding and private equity investments. They aim to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant transactions within the respiratory device sector, such as supporting Archeon in their Series A financing round, which raised funds to expand their range of medical ventilation devices. Additionally, they have invested in Dianosic, a startup focused on solutions for ENT conditions, which may have implications for respiratory health. These transactions highlight Bpifrance's commitment to advancing medical technology in the respiratory device industry.
3. SBRI Healthcare
- Website: sbrihealthcare.co.uk
- Type: Corporate
- Headquarters: Twickenham, England, United Kingdom (UK)
- Founded year: 2009
- Headcount: 11-50
- Number of deals in 2024: 3
- LinkedIn: sbri-healthcare
SBRI Healthcare is a not-for-profit healthcare innovation program based in Twickenham, England, founded in 2009. The organization aims to provide funding and support to innovators and entrepreneurs who are addressing unmet health and care needs within the NHS and social care system. By accelerating the development of innovative technologies and solutions, SBRI Healthcare seeks to improve patient care and increase efficiencies in healthcare delivery. Notably, SBRI Healthcare has been involved in several grant transactions relevant to the respiratory device sector, including funding for Airway Medical, which raised $120,907 in July 2022, and PMD Solutions, which received $80,147 in January 2017. These transactions highlight SBRI Healthcare's commitment to supporting innovations that can enhance respiratory care and management.
4. Novo Holdings
- Website: novoholdings.dk
- Type: Venture Capital
- Headquarters: Hellerup, Denmark
- Founded year: 1999
- Headcount: 51-200
- Number of deals in 2024: 45
- LinkedIn: novo-a-s
Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, they have invested in Inogen, Inc., a leading manufacturer of innovative oxygen technology, providing $20 million in equity financing in 2012 and participating in a Series D round in 2007. Additionally, they have invested in Verona Pharma, which raised significant funds in post-IPO equity rounds, indicating their interest in companies that develop respiratory therapeutics. These transactions highlight Novo Holdings' active role in the respiratory device sector, making them a relevant investor in this field.
5. Almi
- Website: almi.se
- Type: Venture Capital
- Headquarters: Stockholm, Stockholm, Sweden
- Founded year: 1994
- Headcount: 201-500
- Number of deals in 2024: 7
- LinkedIn: almi-ab
Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance the growth and competitiveness of these businesses through tailored financial solutions and guidance. Notably, Almi has invested in several companies within the respiratory device sector, including Monivent, which raised $229,042 in a seed round in 2015, and Asthmatuner, which secured $1,550,683 in a venture round in 2020. These investments highlight Almi's commitment to supporting innovations in respiratory health, alongside their broader investment strategy across various industries.
6. Agoranov
- Website: agoranov.com
- Type: Corporate
- Headquarters: Paris, Île-De-France, France
- Founded year: 2000
- Headcount: 11-50
- Number of deals in 2024: 42
- LinkedIn: agoranov
Agoranov is a startup incubator based in Paris, Île-De-France, France, founded in 2000. They specialize in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. Agoranov has been involved in various funding rounds for early-stage startups, including notable transactions in the respiratory device sector. For instance, they participated in the seed round for Corwave, a company focused on developing innovative solutions for respiratory support. Additionally, they have supported other health-related startups like Hemarina, which raised funds for its medical innovations. Their diverse portfolio and commitment to nurturing startups in the healthcare space make them a significant player in the respiratory device industry.
7. Sofinnova Partners
- Website: sofinnovapartners.com
- Type: Venture Capital
- Headquarters: Paris, Île-De-France, France
- Founded year: 1972
- Headcount: 51-200
- Number of deals in 2024: 25
- LinkedIn: sofinnova-partners
Sofinnova Partners is a venture capital firm based in Paris, Île-De-France, France, specializing in life sciences investments. Founded in 1972, the firm focuses on supporting innovative healthcare startups through funding and strategic guidance, particularly in the biopharma and medtech sectors. Sofinnova has been actively involved in various investment strategies aimed at fostering scientific advancements and sustainability in healthcare. Among their notable transactions, they led a seed financing round for CorVent Medical, which raised $4.5 million to develop the CorVent™ Single-Use Ventilator aimed at addressing respiratory insufficiency. They also participated in funding rounds for Breath Therapeutics, which raised €43.5 million for Phase III trials and commercialization of therapies for respiratory conditions. These investments highlight Sofinnova's engagement in the respiratory device industry, reinforcing their role as a significant player in this sector.
8. European Investment Bank (EIB)
- Website: eib.org
- Type: Corporate
- Headquarters: Luxembourg
- Founded year: 1958
- Headcount: 1001-5000
- Number of deals in 2024: 99
- LinkedIn: european-investment-bank
The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides a range of financial services including loans, equity investments, guarantees, and advisory services. EIB focuses on supporting sustainable projects across various sectors, including healthcare. In recent years, EIB has been involved in significant transactions within the respiratory device context, such as providing $33,703,889 in debt financing to Aerogen, a leader in aerosol drug delivery systems, on March 8, 2019. Additionally, EIB participated in a $40,466,825 post-IPO debt financing for Nyxoah on July 3, 2024, a company that develops solutions for sleep apnea, a condition closely related to respiratory health. These transactions highlight EIB's commitment to supporting innovations in the respiratory device industry, making it a relevant investor in this sector.
9. Scottish Enterprise
- Website: scottish-enterprise.com
- Type: Corporate
- Headquarters: Glasgow, Scotland, United Kingdom (UK)
- Founded year: 1991
- Headcount: 1001-5000
- Number of deals in 2024: 55
- LinkedIn: scottish-enterprise
Scottish Enterprise is a public entity established in 1991, focused on economic development in Scotland. It provides a range of services including funding, business development advice, and support for innovation and exports. In 2024, they have made 55 investments, showcasing their active role in fostering business growth. Notably, they have co-led funding rounds for Pneumagen, a company advancing the clinical development of Neumifil, a treatment for respiratory conditions. Additionally, they participated in a funding round for Nebu-Flow, which is working on inhaled drugs for respiratory disorders. These transactions highlight Scottish Enterprise's involvement in the respiratory device sector, aligning with their mission to enhance Scotland's economic landscape through innovation.
10. Novartis Venture Fund
- Website: nvfund.com
- Type: Venture Capital
- Headquarters: Basel, Basel, Switzerland
- Founded year: 1996
- Headcount: 11-50
- Number of deals in 2024: 10
The Novartis Venture Fund is a venture capital firm based in Basel, Switzerland, specializing in life sciences investments. Founded in 1996, the fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping them develop novel therapeutics and address unmet patient needs. Notably, the fund has been involved in several significant transactions in the respiratory device context, including investments in Pulmatrix, Inc., which is developing drug candidates for COPD and cystic fibrosis, and Enterprise Therapeutics, which is working on muco-regulatory therapies for cystic fibrosis. These investments highlight the fund's commitment to advancing respiratory health through innovative solutions. Additionally, their involvement in Ablation Frontiers, which is focused on investigational devices, further underscores their engagement in the medical device sector, including respiratory applications.
11. Life Sciences Partners (LSP)
- Website: lspvc.com
- Type: Venture Capital
- Headquarters: Amsterdam, North Holland, Netherlands
- Founded year: 1987
- Headcount: 11-50
- Number of deals in 2024: 15
- LinkedIn: lsp-bioventures
Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, Netherlands, specializing in private equity investments within the healthcare sector. Founded in 1987, LSP connects investors with innovative healthcare companies, focusing on drug development and medical technology. They aim to foster advancements in healthcare that address unmet medical needs. Notably, LSP led a $25 million Series B financing round for Neurent Medical, which is developing a neurolysis therapy for rhinitis, a condition affecting the respiratory system. This investment highlights LSP's interest in respiratory health technologies. Additionally, they have been involved in other healthcare investments, showcasing their broad focus while still engaging in relevant respiratory device projects.
12. Gilde Healthcare
- Website: gildehealthcare.com
- Type: Venture Capital
- Headquarters: Utrecht, Utrecht, Netherlands
- Founded year: 1982
- Headcount: 51-200
- Number of deals in 2024: 12
- LinkedIn: gilde-healthcare-partners
Gilde Healthcare is a venture capital firm based in Utrecht, Netherlands, specializing in healthcare investments. Founded in 1982, the firm manages over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare focuses on innovative healthtech and therapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. The firm has a strong track record in the respiratory device industry, having led multiple funding rounds for Vapotherm, a company known for its advanced respiratory care devices, including a $24 million financing round in 2014 and subsequent investments totaling $80 million in later rounds. Additionally, Gilde Healthcare led a $38 million equity financing round for Spire Health in 2021, which aims to enhance its respiratory remote patient monitoring platform. These investments highlight Gilde's strategic focus on supporting companies that are advancing respiratory care technologies.
13. Andera Partners
- Website: anderapartners.com
- Type: Private Equity
- Headquarters: Paris, Île-De-France, France
- Founded year: 1953
- Headcount: 51-200
- Number of deals in 2024: 10
- LinkedIn: anderapartners
Andera Partners is a private equity firm based in Paris, Île-De-France, France, founded in 1953. The firm specializes in investment management, providing financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In 2024, Andera Partners has been active with 10 investments, showcasing their commitment to fostering innovation and growth in their portfolio companies. Notably, they led a Series C financing round for SoniVie, which is developing medical technology, and have participated in funding rounds for companies like Medlumics, which operates in the medical device space. Their investment in Verona Pharma, a company that raised significant funds for its post-IPO equity, further highlights their engagement in the life sciences sector, which may include respiratory devices.
14. HBM Healthcare Investments AG
- Website: hbmhealthcare.com
- Type: Venture Capital
- Headquarters: Zug, Zug, Switzerland
- Founded year: 2001
- Headcount: 1001-5000
- Number of deals in 2024: 8
- LinkedIn: hbm-healthcare-investments-ag
HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, specializing in the healthcare sector. Founded in 2001, the firm manages a diversified portfolio of companies in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in the rapidly evolving healthcare market. Notably, they participated in the funding of Vicore Pharma, which raised $46 million to support a phase IIb trial in idiopathic pulmonary fibrosis (IPF), a respiratory condition. Additionally, they have been involved with Vascular Dynamics, a medical device company, contributing to multiple funding rounds, which indicates their interest in medical technologies that may include respiratory devices. This diverse engagement in healthcare investments positions HBM Healthcare Investments as a significant player in the respiratory device sector.
15. Novartis
- Website: novartis.com
- Type: Corporate
- Headquarters: Basel, Basel, Switzerland
- Founded year: 1996
- Headcount: 10001+
- Number of deals in 2024: 7
- LinkedIn: novartis
Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in developing and manufacturing innovative medicines aimed at addressing serious diseases across various therapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Among their notable investments, Novartis participated in the Series A funding round for NuvoAir, which raised $12 million to expand its digital care platform for respiratory health in the U.S. and Europe. This investment highlights Novartis's commitment to advancing technologies that support respiratory care, alongside their other investments in healthcare innovations such as Credence MedSystems and Freenome, which, while not directly related to respiratory devices, showcase their broader interest in health technology.
16. Forbion
- Website: forbion.com
- Type: Venture Capital
- Headquarters: Naarden, North Holland, Netherlands
- Founded year: 2006
- Headcount: 11-50
- Number of deals in 2024: 23
- LinkedIn: forbion-capital-partners
Forbion is a venture capital firm founded in 2006, based in Naarden, North Holland, Netherlands, specializing in the life sciences and bioeconomy sectors. The firm provides investment management and support to biotech companies, helping them develop innovative therapies and technologies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has participated in significant transactions relevant to the respiratory device context, including a $245 million Series A funding for Aiolos Bio, which is focused on developing a drug candidate for moderate-to-severe asthma patients. Additionally, they were involved in funding NeRRe Therapeutics, which raised £20 million for the Phase 2 clinical development of orvepitant, a treatment for chronic cough associated with IPF. These investments highlight Forbion's commitment to advancing therapies that address respiratory conditions.
17. Parkwalk Advisors
- Website: parkwalkadvisors.com
- Type: Venture Capital
- Headquarters: London, England, United Kingdom (UK)
- Founded year: 2009
- Headcount: 11-50
- Number of deals in 2024: 17
- LinkedIn: park-walk-advisors
Parkwalk Advisors is a London-based venture capital investment management firm founded in 2009. They specialize in venture capital investments in university spin-outs and innovative technologies, managing various EIS funds aimed at capital appreciation and tax reliefs for investors. With a focus on high-growth companies, they invest in sectors such as AI, life sciences, and cleantech. Notably, Parkwalk Advisors has been involved in transactions with companies like Ceryx Medical, which raised multiple seed rounds to develop medical technologies, indicating their engagement in the healthcare and potentially respiratory device sectors. Additionally, they have invested in Albus Health, further showcasing their commitment to innovative health solutions.
Respiratory Device Insights: Key Investors in Europe
Investor | Headquarter | Size | Founded | Deals 2024 |
---|---|---|---|---|
European Innovation Council (EIC) | Brussels, Brussels, Belgium | 201-500 | 1958 | 57 |
Bpifrance French Tech Accélération | Paris, Île-De-France, France | 1-10 | 2015 | 198 |
SBRI Healthcare | Twickenham, England, United Kingdom (UK) | 11-50 | 2009 | 3 |
Novo Holdings | Hellerup, Denmark | 51-200 | 1999 | 45 |
Almi | Stockholm, Stockholm, Sweden | 201-500 | 1994 | 7 |
Agoranov | Paris, Île-De-France, France | 11-50 | 2000 | 42 |
Sofinnova Partners | Paris, Île-De-France, France | 51-200 | 1972 | 25 |
European Investment Bank (EIB) | Luxembourg | 1001-5000 | 1958 | 99 |
Scottish Enterprise | Glasgow, Scotland, United Kingdom (UK) | 1001-5000 | 1991 | 55 |
Novartis Venture Fund | Basel, Basel, Switzerland | 11-50 | 1996 | 10 |
Life Sciences Partners (LSP) | Amsterdam, North Holland, Netherlands | 11-50 | 1987 | 15 |
Gilde Healthcare | Utrecht, Utrecht, Netherlands | 51-200 | 1982 | 12 |
Andera Partners | Paris, Île-De-France, France | 51-200 | 1953 | 10 |
HBM Healthcare Investments AG | Zug, Zug, Switzerland | 1001-5000 | 2001 | 8 |
Novartis | Basel, Basel, Switzerland | 10001+ | 1996 | 7 |
Forbion | Naarden, North Holland, Netherlands | 11-50 | 2006 | 23 |
Parkwalk Advisors | London, England, United Kingdom (UK) | 11-50 | 2009 | 17 |
Want to find more investors focusing on the respiratory device industry?
If you want to find more investors that are active in the respiratory deviceindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.With Inven, you'll also get to know:
- Deal History: Number of deals and their sizes.
- Portfolio: Companies they've invested in.
- Contact data: Key dealmakers, including their emails and phonenumbers.
- ...and much more!
Trusted by 700+ companies

















